HyperSight CBCT approached simulation-CT dosimetry for offline adaptive breast radiotherapy
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
More accurate deformable registration lowered estimated bowel dose, but produced nearly identical in-treatment adaptation decisions to simple DVH summation.
In 604 fractions, traffic-light alerts partially identified target undercoverage but were unreliable proxies for organ-at-risk dose changes.
DART predicted clinically triggered head and neck adaptation with 92% sensitivity and specificity using a unified 2-Gy dosimetric threshold.
Mean heart dose increased during esophageal IMPT, while heart-dose–triggered replanning reduced the excess dose in patients requiring adaptation.
BARitOne uses on-treatment diffusion MRI to increase gross tumour dose from 65 to 73 Gy only in predicted non-responders.
Strict exit-dose gamma thresholds correlated with anatomical change and identified all clinically replanned patients in a retrospective validation cohort.
Early three-dimensional CBCT shifts performed no better than chance for identifying patients with at least 3% PTV coverage loss.
Low Dose HyperSight protocols reduced exposure by 55%, while Slow and Large protocols increased imaging dose and accentuated secondary-risk estimates.
Radioactive carbon-11 beams enabled PET-guided range adjustment during irradiation, with biological outcomes matching insufficient, optimal and excessive beam penetration.
Rigid couch correction cannot fully resolve regional posture mismatch, immobilization failure or progressive anatomical change during head and neck radiotherapy.
A single offline replan at fraction 15 captured most achievable dosimetric benefit in simulated head and neck proton therapy.
Synthetic computed tomography from cone-beam computed tomography achieved a 98.7% gamma pass rate for head-and-neck dose recalculation.
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
Weekly monitoring identified week 2 triggers for nodal targets and contralateral parotids, with later week 4 triggers for primary targets.